The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.

Disclosed are a traditional Chinese medicine composition for treating tumours and a preparation method therefor, wherein the composition is prepared from Sophora flavescens, wild Chrysanthemum flower, honeysuckle, mint, Poria cocos, Atractylodes lancea, cinnamon, clove, Astragalus, Ganoderma lucidum, Ligusticum striatum, Aucklandia root and Radix glycyrrhizae. The traditional Chinese medicine composition has an anti-tumour effect.

Disclosed are a traditional Chinese medicine composition for treating tumours and a preparation method therefor, wherein the composition is prepared from Sophora flavescens, wild Chrysanthemum flower, honeysuckle, mint, Poria cocos, Atractylodes lancea, cinnamon, clove, Astragalus, Ganoderma lucidum, Ligusticum striatum, Aucklandia root and Radix glycyrrhizae. The traditional Chinese medicine composition has an anti-tumour effect.

Disclosed are a traditional Chinese medicine composition for treating tumours and a preparation method therefor, wherein the composition is prepared from Sophora flavescens, wild Chrysanthemum flower, honeysuckle, mint, Poria cocos, Atractylodes lancea, cinnamon, clove, Astragalus, Ganoderma lucidum, Ligusticum striatum, Aucklandia root and Radix glycyrrhizae. The traditional Chinese medicine composition has an anti-tumour effect.

Technologies relating to Chinese medicine composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of patients are disclosed. An example composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of a patient, includes: an Astragalus Root; a Ganoderma Spore; a Siberian Ginseng; an Underleaf Pearl; a Honeysuckle Flower; a Chinese Globe Flower; an Isatis Leaf; an Woad Root; a Patchouli; a Forsythia Fruit; an asiatic Pennywort; an Aged Tangerine Peel; a Giant Knotweed; a Reed Rhizome; an Unprepared Licorice Root; and a Fresh Ginger Rhizome.

Technologies relating to Chinese medicine composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of patients are disclosed. An example composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of a patient, includes: an Astragalus Root; a Ganoderma Spore; a Siberian Ginseng; an Underleaf Pearl; a Honeysuckle Flower; a Chinese Globe Flower; an Isatis Leaf; an Woad Root; a Patchouli; a Forsythia Fruit; an asiatic Pennywort; an Aged Tangerine Peel; a Giant Knotweed; a Reed Rhizome; an Unprepared Licorice Root; and a Fresh Ginger Rhizome.

Technologies relating to Chinese medicine composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of patients are disclosed. An example composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of a patient, includes: an Astragalus Root; a Ganoderma Spore; a Siberian Ginseng; an Underleaf Pearl; a Honeysuckle Flower; a Chinese Globe Flower; an Isatis Leaf; an Woad Root; a Patchouli; a Forsythia Fruit; an asiatic Pennywort; an Aged Tangerine Peel; a Giant Knotweed; a Reed Rhizome; an Unprepared Licorice Root; and a Fresh Ginger Rhizome.

A method for making a fiber containing active ingredients from a Chinese herb. The method includes subjecting a fiber material, which is to be combined with active ingredients from the Chinese herb, to be swelled with a solvent of cellulose and then to be impregnated in a solution of an extract of the Chinese herb. The fiber material is a cellulose fiber or a spunlaced nonwoven fabric made thereof. The method requires no use of adhesives. With the method, the fiber material does not need to be subjected to acidic or basic solutions or high temperature, which would cause the active ingredients to be decomposed. The method can provide a cellulose fiber or a nonwoven fabric made thereof, both of which have a higher content of active ingredients from a Chinese herb and higher durability. Furthermore, the method is simple and is easy to control, and thus, suitable for mass production.

A method for decreasing formation of one or more chemiexcitation-induced dark cyclobutane pyrimidine dimers (dCPDs) in a cell or DNA molecule in a subject, who has been exposed to UV radiation, is provided. The method comprises administering to the subject an effective amount of a dCPD quencher within 8 hours after the exposure. The dCPD quencher is selected from the group consisting of ellagic acid, Porphyra Umbilicalis Extract (including Porphyra Umbilicalis Extract (and) Sodium Lactate (and) Lecithin), mycosporine-like amino acids (MAAs) and synthetic analogues thereof, Scutellaria Baicalensis Root Extract, Chrysanthemum Morifolium Leaf Extract, ferulic acid, fused-ring cyanoacrylates, curcumin, epigallocatechin gallate, Scutellaria Baicalensis Root Extract (and) Acacia Catechu Wood Extract, sorbic acid, Polygonum Cuspidatum Root Extract, Acacia Catechu Extract, dipicolinic acid, squalene, Lonicera Japonica (Honeysuckle) Flower Extract, beta-carotene and combinations thereof. The dCPD quencher may be administered to the subject in the absence of UV radiation.

A method for decreasing formation of one or more chemiexcitation-induced dark cyclobutane pyrimidine dimers (dCPDs) in a cell or DNA molecule in a subject, who has been exposed to UV radiation, is provided. The method comprises administering to the subject an effective amount of a dCPD quencher within 8 hours after the exposure. The dCPD quencher is selected from the group consisting of ellagic acid, Porphyra Umbilicalis Extract (including Porphyra Umbilicalis Extract (and) Sodium Lactate (and) Lecithin), mycosporine-like amino acids (MAAs) and synthetic analogues thereof, Scutellaria Baicalensis Root Extract, Chrysanthemum Morifolium Leaf Extract, ferulic acid, fused-ring cyanoacrylates, curcumin, epigallocatechin gallate, Scutellaria Baicalensis Root Extract (and) Acacia Catechu Wood Extract, sorbic acid, Polygonum Cuspidatum Root Extract, Acacia Catechu Extract, dipicolinic acid, squalene, Lonicera Japonica (Honeysuckle) Flower Extract, beta-carotene and combinations thereof. The dCPD quencher may be administered to the subject in the absence of UV radiation.